158 related articles for article (PubMed ID: 14592467)
1. Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis.
Chapman JS; Weiss KL; Curley RW; Highland MA; Clagett-Dame M
Arch Biochem Biophys; 2003 Nov; 419(2):234-43. PubMed ID: 14592467
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
[TBL] [Abstract][Full Text] [Related]
3. The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase- dependent and independent of the retinoic acid receptor.
Anding AL; Chapman JS; Barnett DW; Curley RW; Clagett-Dame M
Cancer Res; 2007 Jul; 67(13):6270-7. PubMed ID: 17616685
[TBL] [Abstract][Full Text] [Related]
4. 4-Hydroxybenzyl modification of the highly teratogenic retinoid, 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic acid (TTNPB), yields a compound that induces apoptosis in breast cancer cells and shows reduced teratogenicity.
Anding AL; Nieves NJ; Abzianidze VV; Collins MD; Curley RW; Clagett-Dame M
Chem Res Toxicol; 2011 Nov; 24(11):1853-61. PubMed ID: 21939267
[TBL] [Abstract][Full Text] [Related]
5. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
[TBL] [Abstract][Full Text] [Related]
6. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
8. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
9. Combinational treatment with retinoic acid derivatives in non-small cell lung carcinoma in vitro.
Choi EJ; Whang YM; Kim SJ; Kim HJ; Kim YH
J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S52-60. PubMed ID: 17923756
[TBL] [Abstract][Full Text] [Related]
10. Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the antineoplasic agent N-(4-hydroxyphenyl) retinamide.
Morales MC; Pérez-Yarza G; Nieto-Rementeria N; Boyano MD; Jangi M; Atencia R; Asumendi A
Anticancer Res; 2005; 25(3B):1945-51. PubMed ID: 16158929
[TBL] [Abstract][Full Text] [Related]
11. Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells.
Ozpolat B; Tari AM; Mehta K; Lopez-Berestein G
Leuk Lymphoma; 2004 May; 45(5):979-85. PubMed ID: 15291358
[TBL] [Abstract][Full Text] [Related]
12. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
Simeone AM; Broemeling LD; Rosenblum J; Tari AM
Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
[TBL] [Abstract][Full Text] [Related]
13. Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells.
Zou C; Zhou J; Qian L; Feugang JM; Liu J; Wang X; Wu S; Ding H; Zou C; Liebert M; Grossman HB
Front Biosci; 2006 Sep; 11():2007-16. PubMed ID: 16720286
[TBL] [Abstract][Full Text] [Related]
14. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
15. Potent cytotoxic effects of novel retinamide derivatives in ovarian cancer cells.
Um SJ; Sin HS; Han HS; Kwon YJ; Kim EJ; Park SH; Kim SY; Bae TS; Park JS; Rho YS
Biol Pharm Bull; 2003 Oct; 26(10):1412-7. PubMed ID: 14519946
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents.
Swanson BN; Newton DL; Roller PP; Sporn MB
J Pharmacol Exp Ther; 1981 Dec; 219(3):632-7. PubMed ID: 6170750
[TBL] [Abstract][Full Text] [Related]
17. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
[TBL] [Abstract][Full Text] [Related]
18. An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
Weiss KL; Alshafie G; Chapman JS; Mershon SM; Abou-Issa H; Clagett-Dame M; Curley RW
Bioorg Med Chem Lett; 2001 Jun; 11(12):1583-6. PubMed ID: 11412986
[TBL] [Abstract][Full Text] [Related]
19. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor.
Moon RC; Pritchard JF; Mehta RG; Nomides CT; Thomas CF; Dinger NM
Carcinogenesis; 1989 Sep; 10(9):1645-9. PubMed ID: 2527636
[TBL] [Abstract][Full Text] [Related]
20. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate.
Bhatnagar R; Abou-Issa H; Curley RW; Koolemans-Beynen A; Moeschberger ML; Webb TE
Biochem Pharmacol; 1991 May; 41(10):1471-7. PubMed ID: 1826840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
